Insulin oral - Emisphere Technologies

Alternative Names: Oral insulin

Latest Information Update: 21 Jan 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Emisphere Technologies
Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
10 Nov 2006 Additional clinical results from a phase II study in patients with type 2 diabetes have been added to the Diabetes therapeutic trials section
02 Nov 2006 Final results from a phase II clinical trial in patients with type 2 diabetes have been added to the Diabetes therapeutic trials section

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com